Maravai Lifesciences Holdings, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

BioCryst Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc.

CymaBay Therapeutics, Inc.

AbCellera Biologics, Inc.

Beam Therapeutics, Inc.

Maravai Lifesciences Holdings, Inc.

Arcellx, Inc.

Arcus Biosciences, Inc.

Recursion Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc.

Ventyx Biosciences, Inc.

Why is Maravai Lifesciences Holdings, Inc. ?

Negative results in Jun 25

OPERATING CASH FLOW(Y) Lowest at USD -22.39 MM
NET SALES(Q) At USD 47.4 MM has Fallen at -20.3%
NET PROFIT(Q) At USD -0.73 MM has Fallen at -112.42%

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -36.83%, its profits have risen by 87.1%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -36.83% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Maravai Lifesciences Holdings, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Maravai Lifesciences Holdings, Inc.

-36.83%

-0.74

80.35%

S&P 500

16.49%

0.83

19.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.84%

EBIT Growth (5y)

-231.01%

EBIT to Interest (avg)

8.08

Debt to EBITDA (avg)

0.39

Net Debt to Equity (avg)

0.04

Sales to Capital Employed (avg)

0.40

Tax Ratio

0.67%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

54.71%

ROE (avg)

64.89%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.02

EV to EBIT

-7.33

EV to EBITDA

-23.39

EV to Capital Employed

1.99

EV to Sales

2.56

PEG Ratio

Dividend Yield

ROCE (Latest)

-27.14%

ROE (Latest)

-34.98%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

DEBTORS TURNOVER RATIO(HY)

Highest at 6.43 times

-26What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -22.39 MM

NET SALES(Q)

At USD 47.4 MM has Fallen at -20.3%

NET PROFIT(Q)

At USD -0.73 MM has Fallen at -112.42%

ROCE(HY)

Lowest at -55.41%

PRE-TAX PROFIT(Q)

At USD -35.26 MM has Fallen at -31.37%

RAW MATERIAL COST(Y)

Grown by 66.71% (YoY

DEBT-EQUITY RATIO (HY)

Highest at 38.05 %

Here's what is working for Maravai Lifesciences Holdings, Inc.

Debtors Turnover Ratio

Highest at 6.43 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Depreciation

Highest at USD 15.39 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Maravai Lifesciences Holdings, Inc.

Net Sales

At USD 47.4 MM has Fallen at -20.3%

over average net sales of the previous four periods of USD 59.47 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Net Profit

At USD -0.73 MM has Fallen at -112.42%

over average net sales of the previous four periods of USD 5.85 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -22.39 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Pre-Tax Profit

At USD -35.26 MM has Fallen at -31.37%

over average net sales of the previous four periods of USD -26.84 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Debt-Equity Ratio

Highest at 38.05 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 66.71% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales